close

Rockwell Medical Technologies, Inc., an integrated biopharmaceutical company, offers products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia. It offers products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. The company is developing proprietary renal drug therapies for iron treatment. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. The company produces acidified concentrate solutions and powders, and bicarbonate concentrate solutions and powders for nationwide distribution, as well as offers blood tubing sets, fistula needles, and a range of ancillary products. It markets its products through direct sales people, independent sales representation companies and agents, and distributors in the United States, Latin America, Asia, and Europe. The company was founded in 1995 and is based in Wixom, Michigan.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	9.20
Volume	71932
Volume Avg	76387
52 Week High	16.91
52 Week Low	6.80
PE	N/A
PE (group average)	39
EPS Year	-1.21
EPS change Q/Q	-70%
EPS change Q/Q Yr ago	-750%
EPS change Q/Q next Q est	-55.26%
EPS change Y/Y	-6.67%
REV change Q/Q	-6.99%
REV change Q/Q Yr ago	-11.33%
EPS next Q est	-0.38
EPS next Y est	-0.63
Divident Annual	0.00
Dividend Yield	0%